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Pemphigoid diseases are subepidermal autoimmune bul-
lous diseases, characterized by autoantibodies against 
structural proteins of the dermal–epidermal junction 
(1). Symptoms of severe pruritus, with or without tense 
blistering of the skin or mucosa, cause a high disease 
burden (2). Basic and clinical research has led to bet-
ter understanding of the mechanisms of pemphigoid 
diseases and novel therapies have been developed (3). 
Nonetheless, there are gaps in our knowledge, and seve-
ral disease areas are not studied yet. These unmet needs 
have not been well-characterized. While available time 
and resources are often limited in research, it is essential 
to address topics relevant to both patients and healthcare 
professionals (4). It is widely recognized now that pa-
tients play an important role in setting the research agenda 
(5). The aim of this study was to explore and prioritize 
unmet needs in pemphigoid diseases from the perspective 
of patients, clinicians and researchers, in order to guide 
future research towards important research topics. A 
secondary aim was to identify points of improvement 
in patient care.
METHODS
A steering group was established in February 2017, consisting of 
a project coordinator (AL), experts on pemphigoid diseases (SAG, 
BH, DZ, MFJ) and a patient representative (MY; director of the 
International Pemphigus and Pemphigoid Foundation (IPPF)). 
A preliminary list of unmet needs was drawn up and discussed 
by the steering group in June 2017 at the IPPF conference in 
Lübeck, Germany. An online anonymous survey was developed 
using Qualtrics survey software (Table SI1), containing questions 
about participants’ characteristics, and unmet needs in pemphigoid 
diseases. Seven or eight pre-listed needs composed by the steering 
group were provided and participants were asked whether they 
recognized the needs as unmet, and to designate a top 3 of the 
most urgent unmet needs. Moreover, participants were asked to 
complement the list composed by the steering group. In addition, 
patients were given questions about satisfaction with patient care, 
and their reasons for (dis)satisfaction.
The survey was distributed internationally between October 
2017 and April 2018. Patients were invited by email via the IPPF, 
and national German and Dutch patient organizations. Clinicians 
and researchers were invited by email via pemphigoid research 
groups, and via the European Academy of Dermatology and Ve-
nereology. Data was exported from Qualtrics directly into SPSS 
Statistics version 23 (IBM, Chicago, IL, USA). Descriptive and 
qualitative statistics were used for data analysis. An overall ranking 
score was calculated by awarding 3 points every time unmet needs 
were ranked highest, 2 points if ranked 2nd, and 1 point if ranked 3rd.
RESULTS
The inclusion and exclusion process is shown in Fig. 1. 
The clinicians’ and researchers’ response rate was 36/99 
(36%). The patients’ response rate is unknown. Partici-
pants characteristics and the top 3 most urgent needs are 
shown in Table I. Patients, clinicians and researchers 
agreed that the most urgent need was improvement in 
therapeutic options for pemphigoid diseases (Table I). In 
addition, patients frequently expressed the need for more 
public information (n = 9) (Table SI1). 
Data on patient satisfaction showed that half of the 
patients were unsatisfied with patient care during the 
diagnostic process, mainly due to misdiagnosis and 
long diagnostic delay (mentioned by 88% of unsatisfied 
patients; Table SII1). Six patients visited more than 5 doc-
tors before a correct diagnosis was made. Patients with 
epidermolysis bullosa acquisita and mucous membrane 
pemphigoid reported a longer diagnostic delay (mean 
90.3 ± 127 and 19.7 ± 23 months), compared with patients 
with bullous pemphigoid (9.0 ± 22 months). Most patients 
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Fig. 1. Flowchart of inclusion and exclusion of study participants. 
BP: bullous pemphigoid; MMP: mucous membrane pemphigoid; EBA: 
epidermolysis bullosa acquisita.
175 people visited the survey  
26 people discontinued before 
answering the first question
42 participants were excluded
21 pemphigus patients 
2   patients filled in the survey twice  
19  participants ended the survey 
before answering an unmet 
need related question 
107  participants completed
134  surveys
71  patients: 
- 52 BP
- 17 MMP




























































Acta Derm Venereol 2019
(76%) were satisfied with current patient care, especially 
in the case of successful treatment (mentioned by 41% of 
satisfied patients), and treatment in centres of expertise 
(mentioned by 37% of satisfied patients) (Table SII1). Tre-
atment side-effects, insurance issues, and poor knowledge 
of the disease among doctors were the main reasons for 
unsatisfactory current patient care.
DISCUSSION
This survey confirmed that a long diagnostic delay and 
suboptimal treatment are important concerns in pemphi-
goid diseases. This study is the first to explore patients’ 
priorities in the field of pemphigoid diseases. The method 
used has some resemblance to the James Lind Alliance 
(JLA) methodology of prioritization of research topics 
(5). The greatest difference is the lack of a finalization 
workshop, in which patients and health professionals dis-
cuss the final prioritization of uncertainties face-to-face. 
Instead, we choose prioritization by survey, considering 
that pemphigoid diseases are rare, and therefore a low 
attendance and a high geographical selection bias would 
be expected. Still, the risk of selection bias was not com-
pletely prevented, as participants from only 3 continents 
were included. Other limitations of this study include a 
relatively low sample size and missing values.
Geographical differences might have caused small de-
viations in the ranked needs (Tables SIII–SV1). Patients 
from North America ranked the need for better treatment 
availability 4th, in contrast to European patients, who rated 
the urgency of this need 7th. This might be explained by 
the lower availability of healthcare in North America than 
in Europe (Table SIII1). Another interesting finding is the 
higher need for easy diagnostic laboratory tests expressed 
by clinicians in North America and Asia, in comparison 
with European clinicians (Table SIV1). Whether this diffe-
rence is caused by approachability, laboratory equipment, 
or by the use of different diagnostic techniques cannot be 
concluded based on our survey data.
In conclusion, further research is needed in order to 
improve and widen the currently available treatment op-
tions for pemphigoid diseases. Patients report a high need 
for shortening the diagnostic delay. Therefore, greater 
awareness of pemphigoid diseases should be promoted. 
We found that after a correct diagnosis was established, 
patients were most satisfied with care in centres of exper-
tise. Focus group sessions might help to provide further 
information on interventions that can improve patient care.
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Table I. Participants characteristics (n = 107) and top 3 ranking of unmet needs in pemphigoid diseases
Patients (n = 71) Clinicians (n = 35) Researchers (n = 28)
Mean age, years (range) 66.6 (34–94)
Mean diagnostic delay: 14.1 months (1 day–15 years)
Mean disease duration: 4.7 years (0–20)
51.9 (28–65)
Setting: Academic 34 (97%)
             Peripheral 1 (3%)
Consider yourself AIBD expert? 
 Yes: 35 (100%)
51.6 (28–65)
Research experience:
 >10 years: 20 (71%)
AIBD main research topic? 
 Yes: 21 (75%), No: 7 (25%)
Continent of origin, n (%)
  Europe 




  1 (1)
21 (60)
  7 (20)
  4 (11)
18 (64)
  6 (21)
  4 (14)










Patients (n = 71)
1. Need for better treatment options 48 (68) 5 (7) 18 (25) 92
2. Need for quicker diagnosis 47 (66) 9 (13) 15 (21) 84
3. Need for more disease awareness 46 (65) 8 (11) 17 (24) 81
Clinicians (n = 35)
1. Need for labelling of new drugs for the indication pemphigoid (anti-CD20, anti-complement, anti-FcRn, anti-neutrophil 
activating pathways) 
30 (86) 4 (11) 1 (3) 53
2. Need for easy laboratory tests to diagnose pemphigoid diseases 27 (77) 5 (14) 3 (9) 38
3. Need for better recognition of non-bullous pemphigoid 30 (86) 3 (9) 2 (6) 37
Researchers (n = 28)
1. Need for more head-to-head randomized controlled trials comparing the effectiveness and safety of current treatments 25 (89) 1 (4) 2 (7) 51
2. Need for understanding of the pathophysiology of pemphigoid for drug development 27 (96) 0 (0) 1 (4) 38
3. Need for understanding trigger mechanism (e.g. infections, drugs) in addition to genetic predisposition 27 (96) 0 (0) 1 (4) 30
*Ranking score was calculated by awarding 3 points for every time an unmet needs was ranked highest, 2 points if ranked 2nd highest and 1 point if ranked 3rd highest.
AIBD: autoimmune blistering diseases.
